Thomas Wayne Gibbs

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.

Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in

Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.

Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.

Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland.